Controlled Substances Need Tamper-Proof Controlled Release, Report Says
This article was originally published in The Pink Sheet Daily
Manufacturers should include safeguard plans against prescription drug abuse in NDA materials, according to a report from Columbia's Center on Addiction & Substance Abuse. The report finds a marked increase in prescription drug abuse and concludes that DTC advertising and internet availability are contributing to the rise.
You may also be interested in...
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.
A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.
A National Institute for Health & Clinical Excellence analysis finds cost per quality-adjusted life year gained as high as $83,000.